Foghorn Therapeutics CEO Adrian Gottschalk shares an update on the company’s FHD-286 combination study in AML and what’s ahead for Foghorn’s pipeline. More from Flagship @ JPM2024 here.
Related Companies
- Foghorn Therapeutics Founded: 2016
More from:
Human Health
